Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2011-2012 seasonal trivalent inactivated influenza vaccine (Instituto Nacional de Salud Pública)
- Development stage
- Phase 3
- Lead developer
- Instituto Nacional de Salud Pública
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The 2011-2012 seasonal trivalent inactivated influenza vaccine is a biologic vaccine evaluated by the Instituto Nacional de Salud Publica, Mexico, specifically for use in pregnant and non-pregnant women. This formulation contains 15μg of hemagglutinin from three specific viral strains: A/California/7/2009 (H1N1)pdm09-like, A/Perth/16/2009 (H3N2)-like, and B/Brisbane/60/2008-like. It is an unadjuvanted, inactivated viral vaccine administered via intramuscular injection. The vaccine was the subject of a Phase 2/3 non-randomized trial (VACINFL2011) to determine its safety and immunogenicity in pregnant women, a population at high risk for severe influenza complications, to ensure protective antibody levels are achieved without significant adverse effects.
- Other names
- 0-Instituto Nacional de Salud Publica, Mexico-influenza2011-2012 Seasonal Trivalent Inactivated Influenza VaccineTIV 2011-2012TIV2011-2012TIV-2011-2012
02
Targets
H1 HA (Influenza A hemagglutinin H1)H3 HA (Influenza A hemagglutinin H3)HA (Hemagglutinin of influenza B/Brisbane/60/2008-like virus)
Beyond the preview
Go deeper on 2011-2012 seasonal trivalent inactivated influenza vaccine (Instituto Nacional de Salud Pública).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 2011-2012 seasonal trivalent inactivated influenza vaccine (Instituto Nacional de Salud Pública).